XiaoMi-AI文件搜索系统
World File Search System列醇
在神经病学中使用大麻二醇的指示
摘要简介：大麻二酚（CBD）是壁va大麻的非精神活性成分，由于其抗惊厥药和神经保护性能，在神经系统条件下显示出治疗潜力。这项研究系统地修改了有关神经病学中CBD指示的文献。目的：分析有关CBD在神经系统疾病中使用的证据，其作用机理，临床功效和安全性。方法论：对已发表的Scielo，Lilacs和Google学术基础进行了定性评论，涵盖了2008年至2023年的出版物。与CBD相关的描述符和神经病学，选择30项相关研究进行详细分析。结果和讨论：CBD在难治性癫痫中表现出有效性作为辅助治疗，减少了Dravet和Lennox-Gastaut综合征的癫痫发作。在帕金森氏病中，它改善了生活质量而不会加剧运动症状。在多发性硬化症中，尽管与THC结合进行了更多研究，但分离的CBD具有神经保护势和免疫调节剂。在自闭症谱系障碍中，它显示出行为改善。其作用机理涉及多种神经化学途径，包括调节血清素能和vany型受体。安全性概况是有利的，但是存在药物相互作用的风险。最终考虑：CBD是神经病学中有前途的替代方案，但是面临着诸如小样本和缺乏剂量标准化的研究之类的局限性。法律和监管问题会影响获得治疗的机会。未来的研究应确定理想剂量，评估长期安全性，并加深对行动机制的理解，以有效地整合CBD在临床实践中。关键字：大麻二酚； CBD;神经病学；癫痫;帕金森氏病；多发性硬化症;自闭症。
白藜芦醇是易怒的肠脑轴的调节器...
Dao等。 发现，在高脂喂养的糖尿病小鼠模型中，白藜芦醇增加了GLP-1的释放[23]。 Pegah等。 与糖尿病基团相比，白藜芦醇和益生菌的结构显着增加了非糖尿病大鼠的GLP-1和总抗氧化能力[24]。 但是，Knop等人进行的一项研究。 证明白藜芦醇并未直接构成GLP-1的释放[25]。 白藜芦醇可能会通过acti vesti基因（例如SIRT1和FOXO基因）来表达GLP-1在肠道和CNS中的影响[16]。 蛋白质的FoxO家族是参与各种生理和病情逻辑过程的转录因子，例如细胞稳态，干细胞维持，癌症，代谢和汽车双耳疾病[26]。 因此，迄今为止，白藜芦醇对释放的白藜芦醇的机械性仍然存在争议。Dao等。发现，在高脂喂养的糖尿病小鼠模型中，白藜芦醇增加了GLP-1的释放[23]。Pegah等。与糖尿病基团相比，白藜芦醇和益生菌的结构显着增加了非糖尿病大鼠的GLP-1和总抗氧化能力[24]。但是，Knop等人进行的一项研究。证明白藜芦醇并未直接构成GLP-1的释放[25]。白藜芦醇可能会通过acti vesti基因（例如SIRT1和FOXO基因）来表达GLP-1在肠道和CNS中的影响[16]。蛋白质的FoxO家族是参与各种生理和病情逻辑过程的转录因子，例如细胞稳态，干细胞维持，癌症，代谢和汽车双耳疾病[26]。因此，迄今为止，白藜芦醇对释放的白藜芦醇的机械性仍然存在争议。
PR PRZ-原丙醇普罗醇盐酸盐片...
指示PRZ-丙醇可在轻度至中度高血压和心绞痛的预防治疗中指出。PRZ-丙醇与噻嗪类样利尿剂和/或外围血管扩张剂兼容。PRZ-丙酚与噻嗪类样利尿剂和/或外周血管扩张剂的组合通常比单独的普萘洛尔更有效。不建议在高血压危机的紧急治疗中使用PRZ-丙醇。老年人：老年患者没有可用的信息。儿科：不建议在儿童中使用PRZ-丙二醇（请参阅警告和预防措施，特殊人群）。
弗里德里希共济失调中补充三烯醇的影响
运输过程中关于动物福利的科学意见回顾了有关主要农场物种的最新科学信息。根据EC法规1/2005 5的结构，安排了新的科学证据以及随之而来的结论和建议。关于运输的适合度，对牛和家禽的建议集中在重复的人道处理和运输前进行仔细检查。在运输途径，在马运输中使用分区，在停止时提供水的强制禁食以及家禽的温度限制是主要建议。建议保持动物群体的稳定性为良好实践，特别强调需要避免混合陌生的猪或山羊。在浇水和喂养间隔，旅行时间和休息时间内，马的持续时间不应超过12小时，而牛则不得超过29小时。马应在运输前一小时和一小时后向水提供水，对于牛来说，应有24小时的恢复期，并获得食物和水。对于兔子来说，在湖泊期间花费的时间应视为旅程时间。马匹的空间津贴应以kg /m 2而不是m 2 /动物给出。对于牛和绵羊，建议应根据与体重相关的异形方程来计算空间津贴。在容器中库存的库存密度的限制应与热条件有关。在导航系统上，应合并温度监测系统。应就要记录的数据类型，
白藜芦醇及其纳米制剂作为抗氧化剂的潜在作用......
癌症的不可控性和转移性使其病情更加恶化和难以预测。因此，许多疗法和药物被用于控制和治疗癌症。然而，除此之外，许多药物会引起各种副作用。在美国，近 8% 的患者因副作用而入院。发达国家的癌症患者更多，这与他们的生活方式有关。有各种植物成分分子，其中白藜芦醇 (RSV) 是最适合癌症的分子，因为它对身体的不良影响明显较小。RSV 通过调节各种途径（如磷酸肌醇 3 激酶 (PI3K)/蛋白激酶 B (AKT)/哺乳动物雷帕霉素靶蛋白 (mTOR) 途径）来抑制细胞增殖的启动和进展。 RSV 降低了细胞周期调节蛋白（如细胞周期蛋白 E、细胞周期蛋白 D1 和增殖细胞核抗原 (PCNA)）的水平，并诱导细胞色素 c 从线粒体释放，导致细胞凋亡或程序性细胞死亡 (PCD)。RSV 的巨大优势也带来了一些挑战，因此，RSV 在水中的溶解度较差，即 0.05 mg/mL。由于 RSV 被肝脏和肠道高度代谢，因此生物利用度较差。令人惊讶的是，RSV 代谢物也会诱导 RSV 的代谢。因此，尿液中以不变形式存在的 RSV 量明显减少。由于生物利用度差、水溶性较低以及在体内停留时间长等挑战，研究人员决定制造纳米载体以实现更好的递送。采用纳米制剂技术，局部渗透率提高 21%，纳米封装得到改善，从而使生物利用度和渗透性提高许多倍。因此，本综述描述了 RSV 及其用于提高抗癌活性的纳米制剂的完整概况以及专利调查。
基于直列拓扑的多频带 SIW 带通滤波器的合成与实现
摘要 — 本文提出了一种用于多频带带通滤波器 (MBPF) 的相似变换方法，将星型拓扑转换为直列拓扑。介绍了一种通用理论技术，用耦合矩阵的相似变换旋转代替传统的通过滤波器综合逐步提取 LC 电路，解决了参数提取过程中的舍入误差，提高了理论综合结果的准确性。直列拓扑的应用大大提高了滤波器设计的灵活性，降低了电路复杂性，简化了高阶 MBPF 的制造。基于基片集成波导 (SIW) 技术，设计和实现了一系列示例，包括三频、四频，特别是首次报道的五频三阶切比雪夫 SIW 带通滤波器。模拟响应与测量结果之间具有良好的一致性，验证了设计的滤波器模型和提出的理论方法。
利物浦约翰列侬机场 2050 年总体规划
利物浦是一座国际化城市。它以商业为基础，保留了引以为豪的贸易传统和对外关注。利物浦约翰列侬机场 (LJLA) 既是通往利物浦市区 (LCR) 的国际门户，也是当地经济的主要推动力，发挥着重要作用。它为该地区提供了约 6,000 个工作岗位，并为 LCR 的经济贡献了 2.5 亿英镑的 GVA。这座充满活力且不断发展的机场的存在也成为利物浦南部重塑的催化剂。机场有潜力做更多的事情，我们渴望发挥这一潜力，造福利物浦市区及其他地区。本总体规划确认了 LJLA 未来的长期愿景，并描述了机场及其周边土地的进一步投资提案。它详细考虑了机场到 2030 年的提案，并提供了到 2050 年的潜在发展的广泛指示。
XIGDUO®（达格列净和盐酸二甲双胍片）
二甲双胍通过肾脏消除，由于肾功能不全患者发生严重不良反应的风险更大，因此 XIGDUO 禁用于严重肾功能不全（估计肾小球滤过率 (eGFR) <30 mL/min/1.73 m 2 ）患者。请参阅肾脏。由于衰老与肾功能下降有关，因此不应在 80 岁以上的患者中开始 XIGDUO 治疗，除非他们的肾功能没有显著下降。对于高龄患者，应仔细滴定 XIGDUO 以确定足够血糖作用的最低剂量。需要更仔细和频繁地监测肾功能，以帮助预防二甲双胍相关的乳酸性酸中毒。见 4.1 剂量注意事项、4.2 推荐剂量和剂量调整、内分泌和代谢、乳酸性酸中毒、7.1.4 老年病学。
列治文山官方规划第 18.2 号修正案
• 该修正案符合《省级政策声明（2020 年）》，该声明要求市政当局规划并适应现有定居区内的集约化和再开发，以创建更可持续的社区并更有效地利用土地和基础设施； • 该修正案符合《成长之地：大金马蹄地区增长计划（2019 年）》，该计划支持实现完整的社区，这些社区具有多样化的土地用途，并方便获得当地商店、服务和公共服务设施； • 该修正案符合《约克区官方计划（2010 年）》，该计划将主题土地指定为“城市区域”，并鼓励在城市区域边界内进行集约化和再开发。此外，建议通过该地区的市政综合审查将这些土地排除在该地区就业用地之外
重新列出了dna de dna delinfócitost
Figura 1: Desenho esquemático dos componentes presentes nas redes extracelulares de DNA em neutrófilos ................................................................................................................................................17 Figura 2: Representação esquemática da via da Netose ........................................................................19 Figura 3: Desenho experimental .................................................................................................................28 Figura 4: Estratégia de análise para avaliar a frequência das populações de CD14+,CD19+, CD4+ e CD8+ após a Marcaçãocomanticorpos antisubpopulaçõescelulares eaquisiçãoporcitometriade fluxo。..................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 38图5：富集淋巴细胞的细胞组成的细胞仪分析。。...................................................................................................................................................39 Figura 6: Avaliação da porcentagem de morte celular por citometria de fluxo ................................... 40 Figure 7: Evaluation, in lymphocyte -enriched crops, by confocal microscopy, of the occurrence of extracellular DNA. 在 ................. 51 Figure 15: SME evaluation of CD4+ and CD8+ T lymphocytes................................... 40 Figure 7: Evaluation, in lymphocyte -enriched crops, by confocal microscopy, of the occurrence of extracellular DNA.在................. 51 Figure 15: SME evaluation of CD4+ and CD8+ T lymphocytes.................. 51 Figure 15: SME evaluation of CD4+ and CD8+ T lymphocytes........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................ .......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 46 Figure 11: Extracellular networks blushed by DAPI do not have actin. ............................... 47 Figure 12 Electronic microscopy assessment of scanning the presence of extracellular networks in lymphocyte -enriched crops. .......................................................................... 50 Figure 13 Electronic Microscopy Evaluation of Internal Morphology Transmission of Lymphocytes. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ......................................................... 52 Figure 16: Evaluation of the percentage of cell death by CD4+ and CD8+ T lymphocyte flow cytometry. .............................................................................................................................................................................................................................................................................................................................................................................................................................................................. 54 在........................................... 46 Figure 11: Extracellular networks blushed by DAPI do not have actin................................ 47 Figure 12 Electronic microscopy assessment of scanning the presence of extracellular networks in lymphocyte -enriched crops. .......................................................................... 50 Figure 13 Electronic Microscopy Evaluation of Internal Morphology Transmission of Lymphocytes. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ......................................................... 52 Figure 16: Evaluation of the percentage of cell death by CD4+ and CD8+ T lymphocyte flow cytometry. .............................................................................................................................................................................................................................................................................................................................................................................................................................................................. 54 在............................... 47 Figure 12 Electronic microscopy assessment of scanning the presence of extracellular networks in lymphocyte -enriched crops........................................................................... 50 Figure 13 Electronic Microscopy Evaluation of Internal Morphology Transmission of Lymphocytes. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ......................................................... 52 Figure 16: Evaluation of the percentage of cell death by CD4+ and CD8+ T lymphocyte flow cytometry. .............................................................................................................................................................................................................................................................................................................................................................................................................................................................. 54 在.......................................................................... 50 Figure 13 Electronic Microscopy Evaluation of Internal Morphology Transmission of Lymphocytes................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................ ........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................ 52 Figure 16: Evaluation of the percentage of cell death by CD4+ and CD8+ T lymphocyte flow cytometry. .............................................................................................................................................................................................................................................................................................................................................................................................................................................................. 54 在......................................................... 52 Figure 16: Evaluation of the percentage of cell death by CD4+ and CD8+ T lymphocyte flow cytometry............................................................................................................................................................................................................................................................................................................................................................................................................................................................... 54 在.............................................................................................................................................................................................................................................................................................................................................................................................................................................................. 54在.............................................. 55 Figure 18 Evaluation by CD107 + cell frequency flow cytometry 56 Figure 19: Immunofluorescence of CD8 +, Lets and CD107. ........................ 58 Figure 21: Evaluation of cellular composition of patient injuries through histopathological analysis by hematoxylin/eosin coloration. ........................................................................59 Figura 22: Avaliação da composição celular de lesões de pacientes com LTA ..................................60 Figura 23 : Avaliação por microscopia confocal de ETs em lesões de pacientes da forma cutânea da LTA . ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. .............................................................................................. 65.............................................. 55 Figure 18 Evaluation by CD107 + cell frequency flow cytometry 56 Figure 19: Immunofluorescence of CD8 +, Lets and CD107......................... 58 Figure 21: Evaluation of cellular composition of patient injuries through histopathological analysis by hematoxylin/eosin coloration. ........................................................................59 Figura 22: Avaliação da composição celular de lesões de pacientes com LTA ..................................60 Figura 23 : Avaliação por microscopia confocal de ETs em lesões de pacientes da forma cutânea da LTA . ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. .............................................................................................. 65........................ 58 Figure 21: Evaluation of cellular composition of patient injuries through histopathological analysis by hematoxylin/eosin coloration.........................................................................59 Figura 22: Avaliação da composição celular de lesões de pacientes com LTA ..................................60 Figura 23 : Avaliação por microscopia confocal de ETs em lesões de pacientes da forma cutânea da LTA .............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 65.............................................................................................. 65